Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics

Cancer

Volumn 119, Issue 2, 2013, Pages 388-394

  Chow, Wong Ho ^a   Shuch, Brian ^a   Linehan, W Marston ^a   Devesa, Susan S ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

histological type; race; renal cell carcinoma; stage at diagnosis; survival

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL RATE; TUMOR VOLUME; UNITED STATES;

AFRICAN AMERICANS; AGED; CARCINOMA, RENAL CELL; DEMOGRAPHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR BURDEN; UNITED STATES;

EID: 84872060596     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27690     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Chow WH, Dong LM, Devesa SS,. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7: 245-257.
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr,. Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281: 1628-1631.
4. Chow WH, Devesa SS,. Contemporary epidemiology of renal cell cancer. Cancer J. 2008; 14: 288-301.
5. Lipworth L, McLaughlin JK, Tarone RE, Blot WJ,. Renal cancer paradox: higher incidence but not higher mortality among African-Americans. Eur J Cancer Prev. 2011; 20: 331-333.
6. Brookman-Amissah S, Kendel F, Spivak I, et al. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int. 2008; 103: 1375-1380.
7. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Publication No. 07-6215. Bethesda, MD: National Institutes of Health; 2007.
8. Lee WK, Byun SS, Kim HH, et al. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study. Int J Urol. 2010; 17: 898-904.
9. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2008; 103: 1496-1500.
10. Leibovich BC, Lohse CM, Crispen P, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010; 183: 1309-1316.
11. Lee JH, Choi JW, Kim YS,. The value of histologic subtyping on outcomes of clear cell and papillary renal cell carcinomas: a meta-analysis. Urology. 2010; 76: 889-894.
12. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML,. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27: 612-624.
13. Patard JJ, Leary E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2011; 23: 2763-2771.
14. Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N,. Rate of renal cell carcinoma subtypes in different races. Int Braz J Urol. 2011; 37: 29-34.
15. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR,. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008; 179: 1704-1708.
16. Berndt SI, Carter B, Schoenberg MP, Newschaffer CJ,. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol. 2007; 25: 3589-3595.
17. Hellenthal NJ, Chamie K, Ramirez ML, deVere White RW,. Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 2009; 181: 1013-1019.
18. Tripathi R, Heilbrun LK, Jain V, Vaishampayan UN,. Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. Urology. 2006; 68: 296-301.
19. Zini L, Perrotte P, Capitanio U, et al. Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU Int. 2008; 103: 889-893.
20. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
21. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence-SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973-2008 varying)-Linked To County Attributes-Total U.S., 1969-2009 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2011 (updated 10/28/2011), based on the November 2010 submission.
22. Ederer F, Axtell LM, Cutler SJ,. The relative survival rate: a statistical methodology. J Natl Cancer Inst Monogr. 1961; 6: 101-121.
23. Surveillance Research Program, National Cancer Institute SEER Stat software, version 7.0.5 [computer program]. Bethesda, MD: National Cancer Institute; 2011. www.seer.cancer.gov/seerstat.
24. Kutikov A, Egleston BL, Wong YN, Uzzo RG,. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010; 28: 311-317.
25. Patel SG, Penson DF, Pabla B, et al. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol. 2012; 187: 816-821.
26. Egan BM, Zhao Y, Axon RN,. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010; 303: 2143-2150.
27. Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010; 363: 918-929.
28. Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology. 2011; 22: 797-804.
29. Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM,. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension. 2011; 58: 579-587.
30. Neuzillet Y, Tillou X, Mathieu R, et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol. 2011; 60: 366-373.
31. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007; 69: 230-235.
32. Shah JB, Margulis V,. In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther. 2010; 10: 837-842.
33. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X,. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis. 2010; 31: 1805-1812.
34. Chow WH, Devesa SS,. Underreporting and misclassification of urinary tract cancer cases on death certificates. Epidemiology. 1996; 7: 517-520.